CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Ann Oncol
; 27(8): 1565-72, 2016 08.
Article
in En
| MEDLINE
| ID: mdl-27234640
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Camptothecin
/
Colorectal Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoembryonic Antigen
/
Proto-Oncogene Proteins p21(ras)
/
Bevacizumab
/
Cetuximab
Type of study:
Clinical_trials
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ann Oncol
Year:
2016
Document type:
Article